Hva Skjer’a ?
Denne tråden er stengt for nye innlegg.
01.10.2021 kl 16:07
225000 aksjer omsatt før 09:10 på stigende priser på en «negativ børsdag»....
Her er det definitivt noe som skjer - stay tuned...
Her er det definitivt noe som skjer - stay tuned...
Redigert 15.09.2021 kl 17:36
Du må logge inn for å svare
focuss skrev Jøss. Hvor hårsår er det mulig å bli da?
Kjør på focuss. Bra med litt balanse her inne. Jeg leser deg dit hen at du har de samme ønsker som alle andre her inne - at bgbio lykkes. Fortsett gravingen👍
focuss
04.02.2021 kl 21:36
10267
Positiv2 skrev 120 (60+60) til sammen i SA og India + 120 (60+60)i UK
Ok takk for svar.
Yngling ØH
04.02.2021 kl 21:44
10201
Det er kanskje også litt markedsføringsverdi å ha den største, mest leste tråden på forumet?
Yngling ØH
04.02.2021 kl 23:51
10075
Dexamethasone:
Reduserer:
TNFα
IL6
IL-1β
IL-8
Bemcentinib
Reduserer:
TNFα
IL6
IL-1β
IL-8
I tillegg reduserer bemcentinib andre interleukins og TGf-beta, ZEB1 m.m.
Reduserer:
TNFα
IL6
IL-1β
IL-8
Bemcentinib
Reduserer:
TNFα
IL6
IL-1β
IL-8
I tillegg reduserer bemcentinib andre interleukins og TGf-beta, ZEB1 m.m.
Yngling ØH
04.02.2021 kl 23:58
10036
Bemcentinib øker P53.
Her er en studie fra 2016:
"p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1
Yue Ma-Lauer, Javier Carbajo-Lozoya, View ORCID ProfileMarco Y. Hein, Marcel A. Müller, Wen Deng, Jian Lei, Benjamin Meyer, Yuri Kusov, Brigitte von Brunn, Dev Raj Bairad, Sabine Hünten, Christian Drosten, Heiko Hermeking, Heinrich Leonhardt, Matthias Mann, Rolf Hilgenfeld, and Albrecht von Brunn
PNAS August 30, 2016 113 (35) E5192-E5201; first published August 12, 2016;
https://doi.org/10.1073/pnas.1603435113
Studien viser at P53 tok knekken på SARS-CoV-1
Her er en studie fra 2016:
"p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1
Yue Ma-Lauer, Javier Carbajo-Lozoya, View ORCID ProfileMarco Y. Hein, Marcel A. Müller, Wen Deng, Jian Lei, Benjamin Meyer, Yuri Kusov, Brigitte von Brunn, Dev Raj Bairad, Sabine Hünten, Christian Drosten, Heiko Hermeking, Heinrich Leonhardt, Matthias Mann, Rolf Hilgenfeld, and Albrecht von Brunn
PNAS August 30, 2016 113 (35) E5192-E5201; first published August 12, 2016;
https://doi.org/10.1073/pnas.1603435113
Studien viser at P53 tok knekken på SARS-CoV-1
Yngling ØH
05.02.2021 kl 00:03
10026
"p53 Degradation by a Coronavirus Papain-like Protease Suppresses Type I Interferon Signaling"
https://www.researchgate.net/post/P53-degradation-as-a-result-of-COVID-19-infection
https://www.researchgate.net/post/P53-degradation-as-a-result-of-COVID-19-infection
Dr No
05.02.2021 kl 00:06
10007
Finnes det tall (%) på hvor mye de forskjellige reduseres med?
Redigert 05.02.2021 kl 00:07
Du må logge inn for å svare
Yngling ØH
05.02.2021 kl 00:08
9971
Press Release
Aug 12 2016
How a tumor suppressor indirectly inhibits coronaviruses
Coronaviruses can cause the highly infectious and potentially lethal respiratory illnesses MERS, SARS and COVID-19.
© CDC/Dr. Fred Murphy/Sylvia Whitfield
Coronaviruses can cause the highly infectious and potentially lethal respiratory illnesses MERS, SARS and COVID-19.
© CDC/Dr. Fred Murphy/Sylvia Whitfield
Contact Person
Dr. Albrecht von Brunn
Ludwig-Maximilians-Universität München
DZIF researchers have discovered that a protein which is well known for its role as a tumor suppressor is also required for inhibition of the replication of the coronavirus that causes SARS. The molecules involved in this antiviral defence mechanism offer attractive and interesting targets for the development of novel antiviral therapeutic strategies. The new findings appear in the renowned journal PNAS.
Not so long ago, human coronaviruses were associated with infections characterized by essentially harmless cold-like symptoms. More recently, however, two new members of the family have emerged that cause the highly infectious and potentially lethal respiratory illnesses MERS (Middle East Respiratory Syndrome) and SARS (Severe Acute Respiratory Syndrome), respectively. A team led by PD Dr. Albrecht von Brunn of the Max von Pettenkofer Institute at LMU (Department of Virology) in collaboration with researchers at the universities of Lübeck and Bonn, has now discovered that a protein which is otherwise known to act as a tumor suppressor inhibits the replication of the SARS coronavirus, and in addition demonstrated how the virus neutralizes its effect.
The SARS and MERS viruses, whose natural hosts are the Chinese horseshoe bat and the dromedary, respectively, have shown that coronaviruses can cross species barriers and are capable of causing epidemics in humans. In the quest for drugs with broad antiviral activity, attention has recently focused on so-called checkpoint proteins in the host cell as possible targets. Specific checkpoint proteins control a number of cellular processes, including progression through the cell cycle, and viruses are known to manipulate the cell cycle to promote their own replication. Moreover, these proteins are attractive targets for antiviral agents because their short-term inhibition can be readily tolerated by the host cell. Von Brunn and his colleagues therefore carried out a screen for checkpoint proteins that interact with viral proteins and are required for the replication of the SARS-CoV. “We actually hadn’t considered the tumor suppressor protein p53 in this context at first, because we didn’t find a direct interaction with coronaviruses,” says von Brunn.
The screening procedure, however, revealed an indirect link between a protein component of SARS-CoV and p53: The researchers noticed that certain viral factors stabilized the host enzyme RCHY1. This enzyme is among those responsible for marking proteins for degradation by a host-cell complex called the proteasome – and p53 is known to be among RCHY1’s targets. By infecting cells in which the gene for p53 had been knocked out, the team went on to probe the functional significance of the link between SARS und p53 further. “We found that in cells that lacked p53, the rate of virus replication is several orders of magnitude higher than that observed in cells in which the p53 is present. We believe this is because p53 normally activates genes that are involved in the cell’s non-specific antiviral defence system,” von Brunn says. By stabilizing RCHY1, the viral proteins with which it interacts promote the destruction of p53, thus drastically weakening the cell’s first line of defence against viral infections. This research was supported by the Federal Ministry for Education and Research (BMBF) and the German Center for Infection Research (DZIF).
https://www.dzif.de/en/how-tumor-suppressor-indirectly-inhibits-coronaviruses
Aug 12 2016
How a tumor suppressor indirectly inhibits coronaviruses
Coronaviruses can cause the highly infectious and potentially lethal respiratory illnesses MERS, SARS and COVID-19.
© CDC/Dr. Fred Murphy/Sylvia Whitfield
Coronaviruses can cause the highly infectious and potentially lethal respiratory illnesses MERS, SARS and COVID-19.
© CDC/Dr. Fred Murphy/Sylvia Whitfield
Contact Person
Dr. Albrecht von Brunn
Ludwig-Maximilians-Universität München
DZIF researchers have discovered that a protein which is well known for its role as a tumor suppressor is also required for inhibition of the replication of the coronavirus that causes SARS. The molecules involved in this antiviral defence mechanism offer attractive and interesting targets for the development of novel antiviral therapeutic strategies. The new findings appear in the renowned journal PNAS.
Not so long ago, human coronaviruses were associated with infections characterized by essentially harmless cold-like symptoms. More recently, however, two new members of the family have emerged that cause the highly infectious and potentially lethal respiratory illnesses MERS (Middle East Respiratory Syndrome) and SARS (Severe Acute Respiratory Syndrome), respectively. A team led by PD Dr. Albrecht von Brunn of the Max von Pettenkofer Institute at LMU (Department of Virology) in collaboration with researchers at the universities of Lübeck and Bonn, has now discovered that a protein which is otherwise known to act as a tumor suppressor inhibits the replication of the SARS coronavirus, and in addition demonstrated how the virus neutralizes its effect.
The SARS and MERS viruses, whose natural hosts are the Chinese horseshoe bat and the dromedary, respectively, have shown that coronaviruses can cross species barriers and are capable of causing epidemics in humans. In the quest for drugs with broad antiviral activity, attention has recently focused on so-called checkpoint proteins in the host cell as possible targets. Specific checkpoint proteins control a number of cellular processes, including progression through the cell cycle, and viruses are known to manipulate the cell cycle to promote their own replication. Moreover, these proteins are attractive targets for antiviral agents because their short-term inhibition can be readily tolerated by the host cell. Von Brunn and his colleagues therefore carried out a screen for checkpoint proteins that interact with viral proteins and are required for the replication of the SARS-CoV. “We actually hadn’t considered the tumor suppressor protein p53 in this context at first, because we didn’t find a direct interaction with coronaviruses,” says von Brunn.
The screening procedure, however, revealed an indirect link between a protein component of SARS-CoV and p53: The researchers noticed that certain viral factors stabilized the host enzyme RCHY1. This enzyme is among those responsible for marking proteins for degradation by a host-cell complex called the proteasome – and p53 is known to be among RCHY1’s targets. By infecting cells in which the gene for p53 had been knocked out, the team went on to probe the functional significance of the link between SARS und p53 further. “We found that in cells that lacked p53, the rate of virus replication is several orders of magnitude higher than that observed in cells in which the p53 is present. We believe this is because p53 normally activates genes that are involved in the cell’s non-specific antiviral defence system,” von Brunn says. By stabilizing RCHY1, the viral proteins with which it interacts promote the destruction of p53, thus drastically weakening the cell’s first line of defence against viral infections. This research was supported by the Federal Ministry for Education and Research (BMBF) and the German Center for Infection Research (DZIF).
https://www.dzif.de/en/how-tumor-suppressor-indirectly-inhibits-coronaviruses
Yngling ØH
05.02.2021 kl 00:11
9953
Ikke som jeg har tilgang til.
Men bemcentinib har multiple effekter mot sars-viruset.
P53 er her kanskje en "ny" virkningsmekanisme, da selskapet ikke har nevnt tidligere at P53 har en virusdrepende effekt mot sars.
Men bemcentinib har multiple effekter mot sars-viruset.
P53 er her kanskje en "ny" virkningsmekanisme, da selskapet ikke har nevnt tidligere at P53 har en virusdrepende effekt mot sars.
Rule
05.02.2021 kl 00:44
9876
Ser meget lovende ud ØH. Fra BGBIO har man kommet med multiple udsagn: stærke forskningsresultater, 80% chance for success (trukket tilbage). CEO Glæder sig til at opdatere markedet m.v. Måske er det helt store spørgsmål hvor meget BGBIO kan tjene på Covid hvis success. Det må have en pæn stor usikkerhed. Hvis bemcentinib er en god kur imod senfølger så er potentialet enormt. Hvis det kan holde folk ude af hospitalerne ligeså. Jeg er meget tungt lastet og tænker vi går en spændende fremtid i møde med og uden covid success. Kom så BGBIO. Lykke til.
Rule
05.02.2021 kl 00:52
9936
kursen siver noget. også siden positivt nyt vedr. NSCLC. Det kan være et godt tegn på at der snart kommer en emission som tunge bagmænd gerne vil så lavt ind i som muligt imod lidt udvanding af småinvestorer. Kanske også derfor yderligere insider køb ikke sker. selskabet er der hvor registrational phase-3 skal startes. det er jo en uhyggelig kulmination med covid19 ca. samtidigt.
BioBull
05.02.2021 kl 12:39
9467
😊Fikk hyggelig melding fra Eshan:
«Jeg jobber med blod kreft og bruker bemcentinib på celler av AML pasienter. Vi har fått noen lovende resultater at bemcentinib kan hjelpe dem å bli kurert.
Men bemcentinib brukes også i forskjellige kreftstuder og gode resultater ble funnet der også.
Sincerely yours,
Ehsan Hajjar
Researcher
Bjørn Tore Gjertsen Group
Department of Clinical Science
+4748342957»
«Jeg jobber med blod kreft og bruker bemcentinib på celler av AML pasienter. Vi har fått noen lovende resultater at bemcentinib kan hjelpe dem å bli kurert.
Men bemcentinib brukes også i forskjellige kreftstuder og gode resultater ble funnet der også.
Sincerely yours,
Ehsan Hajjar
Researcher
Bjørn Tore Gjertsen Group
Department of Clinical Science
+4748342957»
Nanoq
05.02.2021 kl 13:07
9327
Flott initiativ, BioBull! Og en stor TAKK til deg for å dele denne meget positive meldingen fra Ehsan Hajjar.
Yngling ØH
05.02.2021 kl 13:24
9254
https://www.thailandmedical.news/news/india-lying-about-actual-extent-of-covid-19-infections-study-shows-that-cases-in-india-are-nearly-95-times-greater-than-reported
https://www.google.com/amp/s/www.thehindubusinessline.com/news/science/distrust-in-covid-19-vaccine-in-india-fell-by-10-post-vaccination-drive-survey/article33607445.ece/amp/
https://www.google.com/amp/s/www.thehindubusinessline.com/news/science/distrust-in-covid-19-vaccine-in-india-fell-by-10-post-vaccination-drive-survey/article33607445.ece/amp/
Redigert 05.02.2021 kl 13:30
Du må logge inn for å svare
ctrlaltdel
05.02.2021 kl 13:49
9125
Tipper noen må svare for noen. Ikke bare å slippe slik informasjon.
Gullit
05.02.2021 kl 14:01
9068
Lovende resultatet på denne gruppen kan du lese om langt tilbake i tid se eks her
https://www.dagensmedisin.no/pharma/2019/12/09/lovende-bemcentinib-effekt-i-eldre-aml-pasienter/
https://www.dagensmedisin.no/pharma/2019/12/09/lovende-bemcentinib-effekt-i-eldre-aml-pasienter/
klaesp
05.02.2021 kl 14:04
9037
ctrlaltdel skrev Tipper noen må svare for noen. Ikke bare å slippe slik informasjon.
Dette er kjent informasjon i markedet
ctrlaltdel
05.02.2021 kl 14:08
9025
Det er langt fra samme kategori av feil/tips/ osv info. Hvorfor skulle noen her på forumet eller andre nn personer få slik info uten markedet. Det skurrer.... enten er det fake eller så er det fyken.
Gullit
05.02.2021 kl 14:16
8992
Slutt, her fra nyere oppdatering.
https://news.cision.com/no/bergenbio-asa/r/bergenbio-presenterer-oppdaterte-kliniske-data-fra-to-fase-ii-kombinasjonsstudier-av-bemcentinib-i-a,c3249804
https://news.cision.com/no/bergenbio-asa/r/bergenbio-presenterer-oppdaterte-kliniske-data-fra-to-fase-ii-kombinasjonsstudier-av-bemcentinib-i-a,c3249804
Redigert 05.02.2021 kl 14:16
Du må logge inn for å svare
ctrlaltdel
05.02.2021 kl 14:24
9004
Helt fint, reint og greit. Men det er ikke vanlig å få presentert mails/svar fra "forskere" eller andre som sitter tettere enn tett på resultater, her på forumet. Det liker jeg ikke og det skurrer.
Gullit
05.02.2021 kl 14:32
9032
Hadde det vert noe nytt innhold så er jeg enig. Han sier bare att det er bra resultater. Det er blitt nevnt før.. men enig att man bør tenke seg om i børsrelaterte selskap ...
Rule
05.02.2021 kl 15:10
8896
hov hov er der ved at ske noget på kursen nu - raketten tændes frem imod Q4 results på onsdag....?
Yngling ØH
05.02.2021 kl 15:22
8783
Helt uproblematisk. Han sier jo ikke noe som ikke allerede er kjent informasjon.
Yngling ØH
05.02.2021 kl 15:51
8692
Vi nærmer oss stupet...
"End of emergency salary leads to massive savings withdrawals
Since the beginning of the pandemic,
Brazilians have paid more attention to saving
money. But with the end of the government-
sponsored coronavirus emergency salary
program a BRL 600 (USD 1 10) monthly
stipend created in March 2020, halved in
September, and made extinct in December
withdrawals from savings accounts reached
a 26-year peak.
According to the Central Bank, the balance
of savings accounts in January was negative
BRL 18.1 billion (USD 3.3 billion).
The government and Congress are already
considering extending the cash-transfer
program for another three months, with.
monthly payments of BRL 200.
In neighboring countries Peru and Colombia,
the economic effects of the pandemic led to
similar consequences and citizens withdrew
excessive amounts of money from their
pension funds. Millions in the continent have
now emptied their retirement savings."
Kilde: Brazilian Report
"End of emergency salary leads to massive savings withdrawals
Since the beginning of the pandemic,
Brazilians have paid more attention to saving
money. But with the end of the government-
sponsored coronavirus emergency salary
program a BRL 600 (USD 1 10) monthly
stipend created in March 2020, halved in
September, and made extinct in December
withdrawals from savings accounts reached
a 26-year peak.
According to the Central Bank, the balance
of savings accounts in January was negative
BRL 18.1 billion (USD 3.3 billion).
The government and Congress are already
considering extending the cash-transfer
program for another three months, with.
monthly payments of BRL 200.
In neighboring countries Peru and Colombia,
the economic effects of the pandemic led to
similar consequences and citizens withdrew
excessive amounts of money from their
pension funds. Millions in the continent have
now emptied their retirement savings."
Kilde: Brazilian Report
Redigert 05.02.2021 kl 15:51
Du må logge inn for å svare
Hildebart
05.02.2021 kl 16:27
8647
Det var vel ikke særlig høyt volum, så det er nok ikke noe å bry seg nevneverdig om. Kursen vaker jo trolig mellom 31 og 37 inntil videre.
Rule
05.02.2021 kl 16:30
8630
Kursen plejer at sive på lavt volumen - ikke flere sælgere på disse latterlig lave kurser... :-)
Hildebart
05.02.2021 kl 16:36
8603
Kanskje de utålmodige begynner å bli lei nå? Vi har jo ventet en stund på at det skal skje noe.. 😃
klaesp
05.02.2021 kl 17:57
8422
Er spent på hvor mye penger som er brukt, ikke billig å gjennomføre studier.. har ikke forhåpninger til Covid guiding, det er allerede kjent at oppdatering kommer innen Q1... hva tenker dere?
Yngling ØH
05.02.2021 kl 18:03
8491
Spørsmål litt på siden:
Oslo Børs har lagt ned sms-varslingstjenesten sin. Hvor kan man få børsmeldinger som push-varsel eller sms?
Jeg finner ikke tjenesten hos Euronext
Oslo Børs har lagt ned sms-varslingstjenesten sin. Hvor kan man få børsmeldinger som push-varsel eller sms?
Jeg finner ikke tjenesten hos Euronext
Yngling ØH
05.02.2021 kl 18:05
8542
Covid-meldingER.. ( i flertall) kommer på den datoen de meldingene er klar, og uavhengig av andre selskapsmeldinger. Noe annet ville være uvanlig og rart.
Redigert 05.02.2021 kl 18:08
Du må logge inn for å svare
klaesp
05.02.2021 kl 18:17
8538
Selvfølgelig 👍 mange har kanskje forhåpninger om status/guiding covid studier..
Yngling ØH
05.02.2021 kl 19:32
8456
Takk for svar og forslag!
Har av varsling på e-poster på telefonen. Ellers hadde det plinget hele tiden. Sms varsling bedre. Da kommer det vibrasjonsvarsling på klokken også om jeg er i møte o.l.
Har av varsling på e-poster på telefonen. Ellers hadde det plinget hele tiden. Sms varsling bedre. Da kommer det vibrasjonsvarsling på klokken også om jeg er i møte o.l.
Redigert 05.02.2021 kl 19:39
Du må logge inn for å svare
Yngling ØH
05.02.2021 kl 21:36
8227
Resveratrol hemmer ZEB1 betydelig, og som nevnt tidligere, så vil nedregulering av ZEB1 medføre vekttap.
https://pubmed.ncbi.nlm.nih.gov/30421960/
https://www.news-medical.net/amp/news/20201127/Resveratrol-shows-potential-as-SARS-CoV-2-antiviral-study-finds.aspx
https://pubmed.ncbi.nlm.nih.gov/30421960/
https://www.news-medical.net/amp/news/20201127/Resveratrol-shows-potential-as-SARS-CoV-2-antiviral-study-finds.aspx
Redigert 05.02.2021 kl 21:40
Du må logge inn for å svare